Surgery for Traumatic Optic Neuropathy

Sponsor
Shanghai Changzheng Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02711982
Collaborator
RenJi Hospital (Other)
2
1
2
131
0

Study Details

Study Description

Brief Summary

The pathophysiology of Traumatic Optic Neuropathy (TON) include a primary and secondary mechanism of injury. At present, no studies validate a particular approach to the management of TON. There are three management lines for these patients that include 1)observation only;2)medical treatment with high or megadoses of methylprednisolone; and 3)surgical intervention. Studies have shown that forces applied to the frontal bone and malar eminences are transferred and concentrated in the area near the optic canal. The tight adherence of the optic nerve's dural sheath to the periosteum within the optic canal is also thought to contribute to this segment of the nerve being extremely susceptible to the deformative stresses of the skull bones. In this study, investigators aim to make a randomized controlled trial to certify the efficiency of optic nerve canal decompression for TON patients.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

surgical intervention's efficiency and outcome for TON patients will be clearly present after this randomized controlled trial study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study
Study Start Date :
Jan 1, 2010
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Optic nerve decompression

Optic canal and optic nerve sheath decompression within 5 days from trauma occur.

Procedure: Optic canal and optic nerve sheath decompression
within 5 days from trauma
Other Names:
  • optic decompression
  • Active Comparator: methylprednisolone

    a maximum daily dose of 1 g of methylprednisolone

    Drug: methylprednisolone
    within 5 days from trauma
    Other Names:
  • steroids
  • Outcome Measures

    Primary Outcome Measures

    1. Amplitude and Latency of Visual-Evoked Potential [from trauma day to 60 days after trauma]

      Name of Scale: Visual-Evoked Potential Physiological Parameter: Amplitude and Latency Questionnaire: Trauma day and 1 day, 2 days, 3 days, 7 days, 14 days, 30 days and 60 days after trauma. Two more test for the day before surgery(Medical) and the day after surgery(Medical). Measurement collection: Inpatient and outpatient

    Secondary Outcome Measures

    1. Vision level of Visual Acuity [from trauma day to 60 days after trauma]

      Name of Scale: Level Vision and Visual acuity chart from 0.1 to 1.5 Physiological Parameter: light perception, hand motion and Visual Acuity Chart from 0.1 to 1.5 Questionnaire: Trauma day and 1 day, 2 days, 3 days, 7 days, 14 days, 30 days and 60 days after trauma. Two more test for the day before surgery(Medical) and the day after surgery(Medical). Measurement collection: Inpatient and outpatient

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with the history of Traumatic Brain Injury or Craniofacial Trauma

    • Optic nerve compression(intraneural edema, nerve sheath hematoma or canal fracture with impingement)

    • Amplitude and latency abnormal or Ratio of amplitude of abnormal to normal side.

    Exclusion Criteria:
    • Glasgow Coma Scale,Score<8

    • Patients with good Visual Acuity and Visual Evoked Potential amplitude ratio more than 50%

    • Other Contraindications for surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Neurosurgery,ShangHai ChangZheng Hospital ShangHai Shanghai China 200003

    Sponsors and Collaborators

    • Shanghai Changzheng Hospital
    • RenJi Hospital

    Investigators

    • Principal Investigator: Lijun Hou, MD,PhD, Shanghai Changzheng Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hou Lijun, Professor, Shanghai Changzheng Hospital
    ClinicalTrials.gov Identifier:
    NCT02711982
    Other Study ID Numbers:
    • 2016TON Study
    First Posted:
    Mar 17, 2016
    Last Update Posted:
    Mar 17, 2016
    Last Verified:
    Mar 1, 2016

    Study Results

    No Results Posted as of Mar 17, 2016